Elisa Giommoni

1.6k total citations
45 papers, 527 citations indexed

About

Elisa Giommoni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Elisa Giommoni has authored 45 papers receiving a total of 527 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Elisa Giommoni's work include Colorectal Cancer Treatments and Studies (16 papers), Pancreatic and Hepatic Oncology Research (16 papers) and Cancer Genomics and Diagnostics (15 papers). Elisa Giommoni is often cited by papers focused on Colorectal Cancer Treatments and Studies (16 papers), Pancreatic and Hepatic Oncology Research (16 papers) and Cancer Genomics and Diagnostics (15 papers). Elisa Giommoni collaborates with scholars based in Italy, Malaysia and United States. Elisa Giommoni's co-authors include Lorenzo Antonuzzo, Fabio Cianchi, Nicola Schiavone, Ileana Skalamera, Lucia Magnelli, Laura Papucci, Serena Pillozzi, Alessio Biagioni, Francesco Di Costanzo and Marco Brugia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Elisa Giommoni

39 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisa Giommoni Italy 14 314 180 158 138 66 45 527
Yongkui Lu China 11 350 1.1× 259 1.4× 220 1.4× 145 1.1× 92 1.4× 20 657
Nuria Rodrı́guez-Salas Spain 13 307 1.0× 99 0.6× 140 0.9× 114 0.8× 67 1.0× 32 485
Delphine Topart France 12 425 1.4× 234 1.3× 122 0.8× 231 1.7× 52 0.8× 29 606
Daniele Lavacchi Italy 12 303 1.0× 184 1.0× 124 0.8× 85 0.6× 75 1.1× 46 476
Ruixuan Geng China 12 254 0.8× 196 1.1× 234 1.5× 148 1.1× 58 0.9× 29 556
Adrian Goldiș Romania 11 146 0.5× 157 0.9× 133 0.8× 91 0.7× 110 1.7× 27 408
Hanguang Hu China 15 348 1.1× 114 0.6× 113 0.7× 98 0.7× 108 1.6× 47 533
Sorina Tăban Romania 11 218 0.7× 193 1.1× 161 1.0× 107 0.8× 147 2.2× 51 531

Countries citing papers authored by Elisa Giommoni

Since Specialization
Citations

This map shows the geographic impact of Elisa Giommoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Giommoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Giommoni more than expected).

Fields of papers citing papers by Elisa Giommoni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Giommoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Giommoni. The network helps show where Elisa Giommoni may publish in the future.

Co-authorship network of co-authors of Elisa Giommoni

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Giommoni. A scholar is included among the top collaborators of Elisa Giommoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Giommoni. Elisa Giommoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paulet, A. Crastes de, Daniele Lavacchi, Marco Brugia, et al.. (2025). Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift. World Journal of Gastrointestinal Oncology. 17(6). 106707–106707.
2.
Pietrantonio, Filippo, Giovanni Randon, Sara Lonardi, et al.. (2024). Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4002–LBA4002. 3 indexed citations
3.
4.
Lavacchi, Daniele, Fabio Staderini, Marco Brugia, et al.. (2023). TRG-High/ATM-Expressed/SIRT1-Absent Profile as Negative Prognostic Marker after Neoadjuvant Chemotherapy for Gastric Cancer. 8(2). 1 indexed citations
5.
Lavacchi, Daniele, Sara Fancelli, Enrico Caliman, et al.. (2023). Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. International Journal of Molecular Sciences. 24(5). 4877–4877. 11 indexed citations
6.
Costanzo, Francesco Di, et al.. (2023). Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine. Cancers. 15(2). 416–416. 20 indexed citations
7.
8.
Giommoni, Elisa, Serena Pillozzi, Enrico Caliman, et al.. (2023). Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.. Journal of Clinical Oncology. 41(16_suppl). e21144–e21144. 1 indexed citations
9.
Cavaliere, Alessandro, Monica Niger, Antonio Avallone, et al.. (2023). Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes. Cancer Chemotherapy and Pharmacology. 92(6). 501–510.
10.
Caliman, Enrico, Sara Fancelli, Francesca Mazzoni, et al.. (2022). Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications. 32. 100603–100603. 17 indexed citations
11.
12.
Milella, Michèle, Claudio Bassi, Ugo Boggi, et al.. (2021). Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology. 169. 103571–103571. 14 indexed citations
13.
Salvianti, Francesca, Stefania Gelmini, Irene Mancini, et al.. (2021). Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. British Journal of Cancer. 125(1). 94–100. 31 indexed citations
14.
Giommoni, Elisa, Serena Pillozzi, Francesca Mazzoni, et al.. (2020). Somatostatin analogs in pregnant patients with neuroendocrine tumor. Anti-Cancer Drugs. 31(10). 1096–1098. 5 indexed citations
15.
Biagioni, Alessio, Ileana Skalamera, Nicola Schiavone, et al.. (2019). Update on gastric cancer treatments and gene therapies. Cancer and Metastasis Reviews. 38(3). 537–548. 129 indexed citations
16.
17.
Giordano, Guido, Antonio Febbraro, Michèle Milella, et al.. (2016). Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. Journal of Clinical Oncology. 34(15_suppl). 4124–4124. 8 indexed citations
18.
Antonuzzo, Lorenzo, Elisa Giommoni, Davide Pastorelli, et al.. (2015). Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World Journal of Gastroenterology. 21(23). 7281–7288. 10 indexed citations
19.
Lastraioli, Elena, Lapo Bencini, Elisa Bianchini, et al.. (2012). hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Translational Oncology. 5(2). 105–112. 38 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongkui Lu Breakdown of academic impact, for papers by Nuria Rodrı́guez-Salas Breakdown of academic impact, for papers by Delphine Topart Breakdown of academic impact, for papers by Daniele Lavacchi Breakdown of academic impact, for papers by Ruixuan Geng Breakdown of academic impact, for papers by Adrian Goldiș Breakdown of academic impact, for papers by Hanguang Hu Breakdown of academic impact, for papers by Sorina Tăban
Rankless by CCL
2026